Previous close | 154.63 |
Open | 157.25 |
Bid | 148.95 x 800 |
Ask | 157.50 x 800 |
Day's range | 150.09 - 158.00 |
52-week range | 137.21 - 327.32 |
Volume | |
Avg. volume | 512,503 |
Market cap | 8.566B |
Beta (5Y monthly) | 0.98 |
PE ratio (TTM) | 61.10 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base business growth of 37% —Growth driven by combination of base business strength, COVID-related demand, and acquisition revenue WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results f
Webcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDTWALTHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2022 financial results on Wednesday, April 27, 2022. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- month reporting period ended March 31, 2
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 22-23, 2022. Tony J. Hunt, President & Chief Executive Officer, will participate in a fireside chat on Tuesday, March 22, at 9:45 a.m. EDT. A live webcast of the presentation will be accessible through Repligen’s Investor